Dermatologicals
Refine Search
Biotechnology
Colorado, USA-based biotech Enveda Biosciences, which is using AI to translate nature into new medicines, has announced an oversubscribed $130 million Series C funding round led by Kinnevik and FPV. 22 November 2024
Biotechnology
The landscape of atopic dermatitis (AD) treatment is advancing with approvals of oral and topical Janus kinase (JAK) inhibitors across the seven major pharmaceutical markets (7MM; USA, France, Germany, Italy, Spain, UK and Japan). 20 November 2024
Biotechnology
Johnson & Johnson and partner Protagonist Therapeutics have reported positive topline results from two Phase III studies testing a first-in-class oral peptide. 20 November 2024
Biotechnology
Aclaris Therapeutics has announced an exclusive licensing agreement with Biosion for broad rights to two new antibodies. 19 November 2024
Biotechnology
The US Food and Drug Administration (FDA) has accepted for review the resubmission of the supplemental Biologics License Application (sBLA) for Dupixent(dupilumab), Regeneron and partner Sanofi revealed late Friday. 18 November 2024
Pharmaceutical
Danish dermatology specialist LEO Pharma today announced that Swissmedic, Switzerland’s national regulatory agency for approving and overseeing therapeutic products, has granted marketing approval for Anzupgo (delgocitinib) cream. 14 November 2024
Biotechnology
Rubedo Life Sciences, a US biopharma developing first-in-class therapies targeting senescent cells which drive age-related diseases, has announced the appointment of Frederick C Beddingfield III, as chief executive officer and board director. 11 November 2024
Pharmaceutical
Almirall, the Spain-based biopharma, reported a 7.9% increase in net sales for the first nine months of 2024, reaching 728 million euros ($775 million), and an EBITDA rise of 2.9% to $152 million. 11 November 2024
Biotechnology
New research has been published in the Journal of Allergy and Clinical Immunology (JACI) that shows treatment with amlitelimab, an anti-OX40 ligand antibody, significantly reduced symptoms of atopic dermatitis (AD) and was maintained even after treatment stopped. 9 November 2024
Biotechnology
The US Food and Drug Administration (FDA) has granted a Rare Pediatric disease designation for BPM31510T, an investigational treatment for epidermolysis (EB) from BPGbio. 4 November 2024
Pharmaceutical
Denmark’s privately-held dermatology specialist LEO Pharma and Japan’s Kyowa Kirin have revealed that they will terminate the distribution and co-promotion agreement for the psoriasis vulgaris treatment Dovobet Ointment, Gel, and Foam (calcipotriol hydrate / betamethasone dipropionate) in Japan on December 31, 2024. 1 November 2024
Biotechnology
Regeneron Pharmaceuticals today announced financial results for the third quarter of 2024 that beat expectations, but still saw its share price fall more than 6% to $866 in early trading. 31 October 2024
Biotechnology
Treatment with Tremfya (guselkumab) resulted in clear or almost clear skin in the majority of adults with low body surface area (BSA) moderate plaque psoriasis (PsO) with special site involvement who had failed topical treatment, says US healthcare giant Johnson & Johnson. 25 October 2024
Biotechnology
New results show Eli Lilly Ebglyss (lebrikizumab-lbkz) improved skin (including hand and face) and itch among patients with moderate-to-severe atopic dermatitis (eczema) who were previously treated with Dupixent (dupilumab). 25 October 2024
Biosimilars
Iceland-based Alvotech and the US unit of Israel’s of Teva Pharmaceutical Industries today revealed that that the US Food and Drug Administration (FDA) has approved Selarsdi (ustekinumab-aekn) in a new presentation 22 October 2024
Pharmaceutical
Spanish dermatology specialist Almirall (BME: ALM) has announced the successful completion of the decentralized regulatory procedure in Europe for efinaconazole. 15 October 2024
Biotechnology
At last month’s European Academy of Dermatology and Venereology (EADV) congress in Amsterdam, Novartis presented new early and long-term Phase III data for remibrutinib in chronic spontaneous urticaria (CSU). 14 October 2024
Biotechnology
The US Food and Drug Administration (FDA) has approved a 2mL pre-filled syringe and pre-filled autoinjector, each containing 320mg of Belgian drugmaker UCB’s Bimzelx (bimekizumab-bkzx), to treat psoriasis. 14 October 2024
Biosimilars
Bio-Thera Solutions and Hungary’s Gedeon Richter have reached an exclusive commercialization and license agreement. 14 October 2024
Biotechnology
Danish dermatology specialist Leo Pharma has revealed plans to cut 200 jobs, marking the company’s fourth workforce reduction since 2022. 11 October 2024
Pharmaceutical
Japan-based Chugai Pharmaceutical has decided to pull out of the Korean joint venture with South Korea’s JW Pharmaceutical that was established on a 50%/50% basis in 1992. 27 November 2019
Pharmaceutical
Privately-held Danish company MC2 Therapeutics today announced that the US Food and Drug Administration has accepted for review its New Drug Application (NDA) for Wynzora Cream (calcipotriene and betamethasone dipropionate; previously dubbed MC2-01 Cream). 21 November 2019
Biotechnology
Weeks after presenting positive Phase III trial results on the company’s key pipeline candidate, bimekizumab, UCB has proven that the first study was no fluke. 15 November 2019
Biotechnology
Danish dermatology specialist Leo Pharma has exercised an option in its collaboration with HitGen, a Chinese company with an early-stage drug discovery platform based on DNA encoded chemical libraries (DELs). 13 November 2019
Pharmaceutical
Privately-held German group Merz has announced plans to reorganize into three independently operating businesses focusing on medical aesthetics, therapeutics and consumer care. 13 November 2019
Pharmaceutical
Spanish drugmaker Almirall has sustained the growth with its most recent financial results that has characterized the company’s turnaround since 2017. 11 November 2019
Pharmaceutical
Shares in AnaptysBio fell over 70% on Friday, after the firm announced disappointing top-line data from its ATLAS trial, a Phase IIb study of etokimab in moderate-to-severe atopic dermatitis. 11 November 2019
Pharmaceutical
Ireland-incorporated drugmaker Allergan has posted quarterly financial results that beat estimates for both revenue and earnings. 5 November 2019
Biotechnology
Third-quarter 2019 sales for US biotech Celgene came in at $4.52 billion, up 16% year-on-year and beating consensus forecasts of $4.41 billion. 1 November 2019
Biotechnology
US drugmaker AbbVie is eyeing a second approval for its JAK inhibitor Rinvoq (upadacitinib), just 11 weeks after announcing its first one. 31 October 2019
Pharmaceutical
French pharma major Sanofi saw its share price dip a fraction by mid-morning, after posting lower third-quarter 2019 sales, hit by a fall in revenue at its primary care business and a drop in its vaccines business. 31 October 2019
Biotechnology
Germany’s MorphoSys and Belgium’s Galapagos today announced the end of the clinical development program of MOR106 in atopic dermatitis. 30 October 2019
Biotechnology
A Type II variation application has been submitted to the European Medicines Agency (EMA) seeking approval for Tremfya (guselkumab) to treat adults with active psoriatic arthritis (PsA). 23 October 2019
Biotechnology
US pharma major Eli Lilly (NYSE: LLY) recently published results from its head-to-head clinical study showing that its interleukin (IL)-17A inhibitor Taltz (ixekizumab) has superiority versus Johnson & Johnson (NYSE: JNJ) subsidiary Janssen’s Tremfya (guselkumab) in moderate-to-severe plaque psoriasis patients. 23 October 2019
Pharmaceutical
The US Food and Drug Administration has approved Israel-headquartered skincare specialist Foamix Pharmaceuticals’ novel Amzeeq (minocycline) topical foam, 4%. 21 October 2019
Biotechnology
Johnson & Johnson’s pharma arm, Janssen, has announced new long-term data from the open-label period of the Phase III VOYAGE 1 clinical trial of Tremfya (guselkumab). 18 October 2019
Biotechnology
Shares in Belgian drugmaker UCB were buoyed by positive Phase III data for the firm’s key pipeline candidate, bimekizumab, on Thursday. 17 October 2019
Biotechnology
Spanish dermatology specialist Almirall looked set to close 4% up on Friday following the publication of new data on its new psoriasis drug Ilumetri (tildrakizumab), aiding its efforts to commercialize the drug in Europe. 11 October 2019
Pharmaceutical
The Switzerland-based company will be led in its next phase of growth and innovation by an experienced management team and board, with proven track records in building sustainable high-growth businesses in pharmaceutical and consumer industries. 9 October 2019
Pharmaceutical
The US Food and Drug Administration has approved Aklief (trifarotene) Cream, 0.005% for the topical treatment of acne, making it the first new retinoid molecule to receive US FDA approval for the treatment of acne in more than 20 years. 7 October 2019
Sign up to receive email updates
Join industry leaders for a daily roundup of biotech & pharma news
Today's issue
Company Spotlight
A US biotech company dedicated to creating oral drugs with an emphasis on indications in virology and immunology.
Copyright © The Pharma Letter 2024 | Headless Content Management with Blaze